Objective  To analyze the clinical manifestations and characteristics of adverse reactions to multi-organ injury caused by camrelizumab, and provide reference for clinical safe drug use.

Methods  Case reports of immune-related multiple organ injury induced by camrelizumab were searched from CNKI, Wanfang, VIP, PubMed, Web of Science and Embase databases from May 2019 to November 2023, and the literature was statistically analyzed.

Results  A total of 22 valid reports were retrieved, and 22 cases were included, including 14 males (63.64%) and 8 females (36.36%). Adverse drug reactions (ADRs) occurred in 18 cases at age over 60 (81.82%). ADRs occurred mostly in 10-35 days (18 cases, 81.82%). The involved organ system damage involved musculoskeletal (16 cases, 72.73%), heart (15 cases, 68.18%), liver (9 cases, 40.91%), nervous system (7 cases, 31.82%). Among them, 16 cases (72.73%) improved or recovered after drug withdrawal and/or symptomatic treatment, and 6 cases (27.27%) died.

Conclusion  The adverse reactions of multiple organ injury caused by camrelizumab mainly occurred in the elderly patients, and the skeletal muscle and myocardium were more damaged, with rapid onset and high mortality, which should be paid great attention to. In clinical use, it is necessary to strengthen drug monitoring, early identification and timely treatment.

1.佘明金. 卡瑞利珠单抗治疗恶性肿瘤的临床研究进展[J]. 癌症进展, 2020, 18(9): 865-869, 890. [She  MJ. Clinical research progress of camrelizumab in the treatment of malignant tumors[J]. Oncology Progress, 2020, 18(9): 865-869, 890.] DOI: 10.11877/j.issn.1672-1535. 2020.18.09.01.

2.Vaddepally R, Doddamani R, Sodavarapu S, et al. Review of immune-related adverse events (irAEs) in non-small-cell lung cancer (NSCLC)-their incidence, management, multiorgan irAEs, and rechallenge[J]. Biomedicines, 2022, 10(4): 790. DOI: 10.3390/biomedicines10040790.

3.Freites-Martinez A, Santana N, Arias-Santiago S, et al. Using the common terminology criteria for adverse events (CTCAE-Version 5.0) to evaluate the severity of adverse events of anticancer therapies[J]. Actas Dermosifiliogr (Engl Ed), 2021, 112(1): 90-92. DOI: 10.1016/j.ad.2019.05.009.

4.符茗铨, 邢明远. 1例卡瑞利珠单抗治疗非小细胞肺癌后出现多器官功能损伤的临床分析[J]. 中南药学, 2022, 20(3): 703-706. [Fu MQ, Xing MY. Clinical analysis of a case with multiple organ dysfunction after camrelizumab treatment for non-small cell lung cancer[J]. Central South Pharmacy, 2022, 20(3): 703-706.] DOI: 10.7539/j.issn.1672-2981.2022.03.041.

5.张维, 艾超, 冀召帅, 等. 1例卡瑞利珠单抗致免疫相关性心肌炎并文献分析[J]. 中国药业, 2022, 31(17): 118-121. [Zhang W, Ai C, Ji ZS, et al. Immune associated myocarditis induced by camrelizumab: a case report and literature analysis[J]. China Pharmaceuticals, 2022, 31(17): 118-121.] DOI: 10.3969/j.issn.1006-4931.2022.17.031.

6.闫丽荣, 陈刚. 1例卡瑞利珠单抗致重度心肌炎不良反应及临床分析[J]. 肿瘤药学, 2022, 12(1): 136-140. [Yan LR, Chen G. Clinical analysis of a case of severe myocarditis induced by camrelizumab[J]. Anti-Tumor Pharmacy, 2022, 12(1): 136-140.] DOI: 10.3969/j.issn.2095-1264.2022.01.22.

7.蒋巧俐, 罗国庆. 卡瑞利珠单抗联合阿帕替尼致多器官功能衰竭1例[J]. 海峡药学, 2022, 34(9): 138-141. [Jiang QL, Luo GQ. A case of multiple organ failure caused by camrelizumab combined with apatinib[J]. Strait Pharmaceutical Journal, 2022, 34(9): 138-141.] DOI: 10.3969/j.issn.1006-3765.2022.09.040.

8.田媛, 翁丹卉, 周婷. 卡瑞利珠单抗治疗复发性子宫颈癌引发免疫性心肌炎1例[J]. 安徽医学, 2023, 44(6): 743-745. [Tian Y, Weng DH, Zhou T. A case of immune myocarditis induced by camrelizumab treatment for recurrent cervical cancer[J]. Anhui Medical Journal, 2023, 44(6): 743-745.] DOI: 10.3969/j.issn.1000- 0399.2023.06.028.

9.袁军, 董芹芹, 胡怀强, 等. 卡瑞利珠单抗治疗胃腺癌致周围神经病变及横纹肌溶解病变1例报告[J]. 中风与神经疾病杂志, 2022, 39(8): 748-750. [Yuan J, Dong  QQ, Hu HQ, et al. A case report of peripheral neuropathy and rhabdomyolysis induced by camrelizumab treatment in gastric adenocarcinoma[J]. Journal of Apoplexy and Nervous Diseases, 2022, 39(8): 748-750.] DOI: 10.19845/j.cnki.zfysjjbzz.2022.0187.

10.王征, 侯维, 郑素军. 卡瑞利珠单抗治疗原发性肝癌致肌炎及横纹肌溶解综合征一例报告[J]. 北京医学, 2021, 43(9): 941-942. [Wang Z, Hou W, Zheng SJ. A case report of myositis and rhabdomyolysis syndrome induced by camrelizumab treatment in primary liver cancer[J]. Beijing Medical Journal, 2021, 43(9): 941-942.] DOI: 10.15932/j.0253-9713.2021.09.027.

11.杨蓓蓓, 万宁, 刘子昀, 等. 卡瑞利珠单抗致1例肺癌患者免疫性心肌炎的药学监护[J]. 药物流行病学杂志, 2022, 31(5): 327-331. [Yang BB, Wan N, Liu ZJ, et al. Pharmaceutical caring of immune myocarditis induced by camrelizumab[J]. Chinese Journal of Pharmacoepidemiology, 2022, 31(5): 327-331.] DOI: 10.19960/j.cnki.issn1005-0698.2022.05.007.

12.张扬, 曾芳, 刘易慧. 卡瑞利珠单抗致肌炎心肌炎肝损伤及重症肌无力1例[J]. 医药导报, 2023, 42(9): 1421-1423. [Zhang Y, Zeng F, Liu YH.A case of camrelizumab-induced myositis, myocarditis, liver damage, and severe myasthenia gravis[J]. Herald of Medicine, 2023, 42(9): 1421-1423.] DOI: 10.3870/j.issn.1004-0781. 2023.09.026.

13.李琳, 刘文辉, 刘艺平, 等. 卡瑞利珠单抗致免疫相关骨骼肌和心肌损伤[J]. 药物不良反应杂志, 2021, 23(8): 447-448. [Li L, Liu WH, Liu YP, et al. Immunerelated skeletal muscle and myocardium injury induced by camrelizumab[J]. Adverse Drug Reactions Journal, 2021, 23(8): 447-448.] DOI: 10.3760/cma.j.cn114015-20201210-01229.

14.李梦娇, 梁平, 单彬, 等. 卡瑞利珠单抗致免疫相关性多器官损伤一例[J].临床药物治疗杂志, 2023, 21(4): 85-88. [Li MJ, Liang P, Shan B, et al. Immune-related multiple organ dysfunction induced by camrelizumab treatment: a case report[J]. Clinical Medication Journal, 2023, 21(4): 85-88.] DOI: 10.3969/j.issn.1672-3384. 2023.04.018.

15.聂新, 吴小源, 贺春语. 免疫检查点抑制剂治疗肺腺癌相关多系统不良反应1例[J]. 中国临床案例成果数据库, 2023, 5(1): E01138-E01138. [Nie X, Wu XY, He CY. A case of immune checkpoint inhibitors related to multiple system adverse reactions in the treatment of lung adenocarcinoma[J]. Chinese Medical Case Repository, 2023, 5(1)E01138-E01138.] DOI: 10.3760/cma.j.cmcr.2023.e01138.

16.李阳, 默峰, 辛志飞, 等. 特殊临床表现多系统免疫相关不良事件1例[J]. 临床荟萃, 2023, 38(7): 633-637.[Li Y, Mo F, Xin ZF, et al. Multiple immune related adverse events with special clinical manifestations: a caser eport[J]. Clinical Focus, 2023, 38(7): 633-637.] DOI: 10.3969/j.issn.1004-583X.2023.07.099.

17.续广娟, 周琴, 陈喆. 注射用卡瑞利珠单抗致糖尿病酮症酸中毒合并血小板减少1例[J]. 中国药师, 2021, 24(3): 531-534. [Xu GJ, Zhou Q, Chen Z. A case of diabetic ketoacidosis and thrombocytopenia induced by camrelizumab injection[J]. China Pharmacist, 2021, 24(3): 531-534.] DOI: 10.3969/j.issn.1008-049X.2021.03.025.

18.Zhang B, Gyawali L, Liu Z, et al. Camrelizumab-related lethal arrhythmias and myasthenic crisis in a patient with metastatic thymoma[J]. Case Rep Cardiol, 2022, 2022: 4042909. DOI: 10.1155/2022/4042909.

19.Bai J, Li D, Yang P, et al. Camrelizumab-related myocarditis and myositis with myasthenia gravis: a case report and literature review[J]. Front Oncol, 2022, 11: 778185. DOI: 10.3389/fonc.2021.778185.

20.Tan Y, Ye Y, Chen L. Fatal immune-related hepatitis with intrahepatic cholestasis and pneumonia associated with camrelizumab: a case report and literature review[J]. Open Med (Wars). 2021, 16(1): 553-557. DOI: 10.1515/med-2021-0267.

21.Mei H, Wen W, Fang K, et al. Immune checkpoint inhibitor-induced myocarditis and myositis in liver cancer patients: a case report and literature review[J]. Front Oncol, 2023, 12: 1088659. DOI: 10.3389/fonc.2022.1088659.

22.Gao L, Li X, Guo Z, et al. Immune checkpoint inhibitor-induced myocarditis with myasthenia gravis overlap syndrome: a case report and literature review[J]. Medicine (Baltimore), 2022, 101(49): e32240. DOI: 10.1097/MD.0000000000032240.

23.Chen Y, Jia Y, Liu Q, et al. Myocarditis related to immune checkpoint inhibitors treatment: two case reports and literature review[J]. Ann Palliat Med, 2021, 10(7): 8512-8517. DOI: 10.21037/apm-20-2620.

24.Zhang C, Qin S, Zuo Z. Immune-related myocarditis in two patients receiving camrelizumab therapy and document analysis[J]. J Oncol Pharm Pract, 2022, 28(6): 1350-1356. DOI: 10.1177/10781552211027339.

25.Bao Z, Sun X, Chen W, et al. Two severe adverse events triggered by an anti-PD-1 immune checkpoint inhibitor in an advanced lung cancer patient: a case report and review of the literature[J]. Ann Transl Med, 2021, 9(16): 1358. DOI: 10.21037/atm-21-4167.

26.Johnson DB, Balko JM. Biomarkers for immunotherapy toxicity: are cytokines the answer?[J]. Clin Cancer Res, 2019, 25(5): 1452-1454. DOI: 10.1158/1078-0432.CCR-18-3858.

27.Kuhnly NM, Coviello J. Immune checkpoint inhibitor-related myocarditis: recognition, surveillance, and management[J]. Clin J Oncol Nurs, 2022, 26(1): 54-60. DOI: 10.1188/22.CJON.54-60.

28.中国抗癌协会整合肿瘤心脏病学分会, 中华医学会心血管病学分会肿瘤心脏病学学组, 中国医师协会心血管内科医师分会肿瘤心脏病学专业委员会, 等. 免疫检查点抑制剂相关心肌炎监测与管理中国专家共识(2020版)[J]. 中国肿瘤临床, 2020, 47(20): 1027-1038. DOI: 10.3969/j.issn.1000-8179.2020.20.148.

29.Markham A, Keam SJ. Correction to: camrelizumab: first global approval[J]. Drugs, 2019, 79(13): 1497. DOI: 10.1007/s40265-019-01191-0.

30.Moslehi JJ, Salem JE, Sosman JA, et al. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis[J]. Lancet, 2018, 391(10124): 933. DOI: 10.1016/S0140-6736(18)30533-6.

31.孙雯娟, 胡扬, 徐燕, 等. 帕博利珠单抗致患者肌炎伴重症肌无力的用药分析[J]. 中国临床药理学杂志, 2023, 39(7): 1037-1039. [Sun WJ, Hu Y, Xu Y, et al. Pharmaceutical care of clinical pharmacists participating in immune checkpoint inhibitor induced myositis with myasthenia gravis[J]. The Chinese Journal of Clinical Pharmacology, 2023, 39(7): 1037-1039.] DOI: 10.13699/j.cnki.1001－6821.2023.07.027.

32.徐婵, 李婷婷. 帕博利珠单抗致暴发性心肌炎和2型糖尿病1例[J]. 医药导报, 2022, 41(12): 1876-1878. [Xu C, Li TT. A case of pembrolizumab-induced fulminant myocarditis and type 2 diabetes mellitus[J]. Herald of Medicine, 2022, 41(12): 1876-1878.] DOI: 10.3870/j.issn.1004-0781.2022.12.027.

33.顾永丽, 孙增先. 帕博利珠单抗致免疫相关性肺炎和心肌炎1例[J]. 中国新药与临床杂志, 2021, 40(2): 155-157. [Gu YL, Sun ZX. One case of immune-related pneumonia and myocarditis induced by pembrolizumab[J]. Chinese Journal of New Drugs and Clinical Remedies, 2021, 40(2): 155-157.] DOI: 10.14109/j.cnki.xyylc.2021. 02.16.

34.梁瑜, 孟真, 李祥鹏, 等. 帕博利珠单抗致免疫相关性肌炎合并心肌炎肝损伤患者的药学服务[J]. 医药导报, 2023, 42(4): 575-578. [Liang Y, Meng Z, Li XP, et al. Pharmaceutical service for a patient with pembrolizumab-induced immune-related myositis combined with myocarditis and liver damage[J]. Herald of Medicine, 2023, 42(4): 575-578.] DOI: 10.3870/j.issn.1004-0781. 2023.04.021.

35.包涵, 郑亚萍. 子宫内膜癌患者输注帕博利珠单抗致免疫性肠炎伴心房颤动1例的护理体会[J]. 护理与康复, 2022, 21(4): 74-75. [Bao H, Zheng YP. Nursing experience of a case with pembrolizumab-induced immune enteritis and atrial fibrillation in a patient with endometrial carcinoma[J]. Nursing and Rehabilitation, 2022, 21(4): 74-75.] DOI: 10.3969/j.issn.1671-9875.2020.04.024.

36.孙玲玲, 周广洁, 张丽娜, 等. 纳武利尤单抗致暴发性免疫相关不良事件1例[J]. 中国医院药学杂志, 2024, 44(11): 1359-1362. [Sun LL, Zhou GJ, Zhang LN, et al. Immune-related fulminant adverse events induced by nivolumab: one case report[J]. Chinese Journal of Hospital Pharmacy, 2024, 44(11): 1359-1362.] DOI: 10.13286/j.1001-5213.2024.11.21.

37.Saishu Y, Yoshida T, Seino Y, et al. Nivolumab-related myasthenia gravis with myositis requiring prolonged mechanical ventilation: a case report[J]. J Med Case Rep, 2022, 16(1): 61. DOI: 10.1186/s13256-022-03286-x.

38.Monge C, Maeng H, Brofferio A, et al. Myocarditis in a patient treated with Nivolumab and PROSTVAC: a case report[J]. J Immunother Cancer, 2018, 6(1): 150. DOI: 10.1186/s40425-018-0473-0.

39.Kim JS, Nam TS, Kim J, et al. Myasthenia gravis and myopathy after nivolumab treatment for non-small cell lung carcinoma: a case report[J]. Thorac Cancer, 2019, 10(10): 2045-2049. DOI: 10.1111/1759-7714.13177.

40.Abushalha K, Abulaimoun S, Silberstein PT. So slow, so fast, a case of nivolumab-induced hypothyroidism with subsequent rhabdomyolysis[J]. Immunotherapy, 2020, 12(9): 625-628. DOI: 10.2217/imt-2020-0053.

41.Wang F, Sun X, Qin S, et al. A retrospective study of immune checkpoint inhibitor-associated myocarditis in a single center in China[J]. Chin Clin Oncol, 2020, 9(2): 16. DOI: 10.21037/cco.2020.03.08.

42.Samani A, Zhang S, Spiers L, et al. Impact of age on the toxicity of immune checkpoint inhibition[J]. J Immunother Cancer, 2020, 8(2): e000871. DOI: 10.1136/jitc-2020-000871.

43.Louvel G, Bahleda R, Ammari S, et al. Immunotherapy and pulmonary toxicities: can concomitant immune-checkpoint inhibitors with radiotherapy increase the risk of radiation pneumonitis?[J]. Eur Respir J, 2018, 51(1): 1701737. DOI: 10.1183/13993003.01737-2017.

44.Sławiński G, Wrona A, Dąbrowska-Kugacka A, et al. Immune checkpoint inhibitors and cardiac toxicity in patients treated for non-small lung cancer: a review[J]. Int J Mol Sci, 2020, 21(19): 7195. DOI: 10.3390/ijms21197195.

45.Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade[J]. N Engl J Med, 2018, 378(2): 158-168. DOI: 10.1056/NEJMra1703481.

46.Raikhelkar J, Uriel N. Immune checkpoint inhibitor myocarditis[J]. Curr Opin Cardiol, 2019, 34(3): 303-306. DOI: 10.1097/HCO.0000000000000622.

47.Suresh K, Naidoo J, Lin CT, et al. Immune checkpoint immunotherapy for non-small cell lung cancer: benefits and pulmonary toxicities[J]. Chest, 2018, 154(6): 1416-1423. DOI: 10.1016/j.chest.2018.08.1048.

48.Crocetto F, Ferro M, Buonerba C, et al. Comparing cardiovascular adverse events in cancer patients: A meta-analysis of combination therapy with angiogenesis inhibitors and immune checkpoint inhibitors versus angiogenesis inhibitors alone[J]. Crit Rev Oncol Hematol, 2023, 188: 104059. DOI: 10.1016/j.critrevonc.2023.104059.

49.Gu T, Jiang A, Zhou C, et al. Adverse reactions associated with immune checkpoint inhibitors and bevacizumab: a pharmacovigilance analysis[J]. Int J Cancer, 2023, 152(3): 480-495. DOI: 10.1002/ijc.34332.

50.Brahmer JR, Lacchetti C, Thompson JA. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: american society of clinical oncology clinical practice guideline summary[J]. J Oncol Pract, 2018, 14(4): 247-249. DOI: 10.1200/JOP.18.00005.